title: Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients.
abstract: The pathogenesis of veno-occlusive disease (VOD) of the liver appears to be secondary to endothelial damage of terminal hepatic venules, which leads to activation of the coagulation cascade, fibrin deposition, and eventual fibrous obliteration of the hepatic venules. Patients with VOD usually present with jaundice, hepatomegaly, weight gain, and ascites. This complication is usually associated with a high mortality rate. We report here the frequency and treatment of VOD in our autologous bone marrow transplant (BMT) patient population. Three of 15 (20%) children (median age 9 years) developed VOD and were treated with recombinant tissue plasminogen activator (rt-PA). Two of these three patients were prepared for BMT with busulfan (16 mg/kg) and cyclophosphamide (Cytoxan, 200 mg/kg), while the other child received cytosine arabinoside (ARA-C 18 g/m2), Cytoxan (3,600 mg/m2) and total body irradiation (TBI, 1,400 y). VOD developed between days 7-24 posttransplant. Clotting studies obtained pretransplant and during VOD included prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, fibrin-degradation product (FDP), proteins C and S, and platelet count. There was no correlation between the incidence of VOD and coagulation status. All patients had normal pretransplant clotting studies. However, protein C levels were noted to be consistently low for those patients at the time of VOD. All three patients received rt-PA at a dose of 0.25-0.5 mg/kg for 4 days. This dose produced increased levels of FDP but did not significantly prolong PT nor PTT. Two of the patients had dramatic responses and had complete resolution of VOD within 6-12 days from the start of therapy. The other patient died of fulminant hepatic failure. It seems that rt-PA is effective in VOD of the liver, which may be associated with low protein C level.
authors.affiliation: Department of Pediatrics, Louisiana State University Medical Center School of Medicine, New Orleans.
authors.forename: L C
authors.initials: LC
authors.lastname: Yu
authors.forename: I
authors.initials: I
authors.lastname: Malkani
authors.forename: O
authors.initials: O
authors.lastname: Regueira
authors.forename: D L
authors.initials: DL
authors.lastname: Ode
authors.forename: R P
authors.initials: RP
authors.lastname: Warrier
mesh_terms: D000293:Adolescent; D000328:Adult; D001201:Ascites / Q000209:etiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy*; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008297:Male; D010996:Pleural Effusion / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator